Clinical Trial Update: Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line therapy for extensive-stage small cell lung cancer using a combination of trilaciclib, envafolimab, etoposide, and carbopl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)
• Envafolimab (envafolimab)
• Paraplatin (Carboplatin)
• Toposar (Etoposide)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer, Small Cell | Phase 2 | Status: RECRUITING